Strategic Clinical Trial Launched to Standardize Companion Diagnostics

AstraZeneca (AZN) has initiated the Genomet clinical trial (NCT07613424) to validate the reliability of c-MET companion diagnostics (CDx) for patients with first-line non-small cell lung cancer (NSCLC). This study is designed to evaluate the concordance of c-MET overexpression across various biomarker testing methods, including next-generation sequencing (NGS) and immunohistochemistry (IHC). As the targeted therapy market matures, accurate patient selection has become a critical factor in the commercial success of drugs. This initiative by a multinational pharmaceutical company to reduce noise in clinical data and enhance the precision of precision medicine can be interpreted as an effort to standardize practices.

Overcoming Biomarker Discordance Issues and Technical Barriers

In actual clinical practice, technical discordance issues exist, where the presence or absence of c-MET mutations and amplifications may be interpreted differently depending on the testing institution or diagnostic platform. Misdiagnosis or interpretation errors can lead to missed opportunities for optimal treatment, which directly impacts the sales of the pharmaceutical company's targeted therapies. AstraZeneca aims to enroll approximately 1,000 patients to objectively quantify the reliability of biomarker profiling using metrics such as OPA/PPA/NPA. By proactively overcoming technical barriers, the company intends to lower the clinical entry barrier for its pipeline and gain a leading position in the diagnostics market.

Laying the Foundation for Global Commercialization of Savolitinib

This companion diagnostics study is a cornerstone for AstraZeneca's global expansion of savolitinib (Orpathys), a c-MET inhibitor co-developed with HUTCHMED (HCM). Novartis' Tabrecta (capmatinib) and Merck KGaA's Tepmetko (tepotinib) have already gained FDA approval and established a presence in the market. In response, AstraZeneca is simultaneously pursuing a Phase 3 clinical trial (SAFFRON study) combining savolitinib with its blockbuster EGFR inhibitor, Tagrisso (osimertinib), while also standardizing companion diagnostics to build an independent ecosystem.

Securing the Combination Therapy Market and Creating Synergy

AstraZeneca is strategically planning to include not only patients with c-MET single mutations but also those with MET amplification as a resistance mechanism to Tagrisso. The Genomet study analyzes cohorts of EGFR-mutant patients (Cohort 1), patients without gene mutations (Cohort 2), and other actionable mutation cohorts (Cohort 3) to achieve this. By comprehensively screening for EGFR, HER2, and PD-L1 mutations at the diagnostic stage, the company aims to maximize the synergy between Tagrisso, savolitinib, and Imfinzi (durvalumab), its other oncology pipeline products.

Competing for Dominance in the $30 Billion NSCLC Market

The global non-small cell lung cancer treatment market is approximately $26 billion, making it one of the most competitive areas in oncology. Given the recent trend of large pharmaceutical companies with precision diagnostics platforms also dominating the treatment market, diagnostic standardization is a key competitive advantage. AstraZeneca plans to complete the primary endpoint evaluation of the Genomet trial by the first half of 2027 and accelerate clinical development based on this data. Ultimately, securing precise screening technology will be the key to achieving both increased prescription volume and market share defense.